Navigation Links
Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
Date:6/15/2009

NEW YORK, June 15 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it will be added to the broad-market Russell 3000(R) Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 26, 2009. According to the preliminary list of additions posted June 12, 2009 on www.russell.com, selection to the Russell 3000(R) Index means Delcath is automatically included in the popular Russell 2000(R) Index, which measures the performance of approximately 2,000 small-cap U.S. securities.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

About Russell:

Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell has $136 billion in assets under management as of March 31, 2009, and serves individual, institutional and advisor clients in more than 40 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.

About Delcath Systems, Inc.:

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from enter
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Delcath Enters Agreement to Sell 869,565 Units
2. Delcath Systems Granted Third Orphan Drug Designation
3. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
6. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
7. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
8. Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems
9. Penguin Computing Forms OEM Agreement with Applied Biosystems for Scyld ClusterWare
10. SANYO Donates Air Purification Systems Effective Against Flu Viruses to New York Airports and Schools
11. OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., Nov. 19 Arlington Medical Resour...ding driver of antibiotic selection in nosocomial ...inst gram-positive and gram-negative pathogens. Du...omial pneumonia, surveyed European physicians reve...e appropriate coverage against common pathogens, p...
(Date:11/19/2009)...nd recognized refractive and cataract surgery expe...their fellow surgeons up-to-date on the latest dev...urgery, and ophthalmology in general at the recent...O) annual meeting in San Francisco, California. Dr... Huang, MD, Dr. Randy Epstein, Dr. William Trattle...
(Date:11/19/2009)...9 AFFiRiS AG will focus its,Alzhei...an unexpectedly early,stage of development: the va...e II clinical trial early in 2010. This decision b...f two Phase I trials with the candidates,AD01 and ...irst interim,analysis of the secondary endpoints a...
(Date:11/18/2009)...nd explosive materials and persons who have been i...ional Institute of Standards and Technology (NIST)...urity, has developed a new certified reference mat...ce Particulate Explosives. Compatible with field a...ul in calibrating, testing and developing standard...
Breaking Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3New NIST trace explosives standard slated for homeland security duty 2
...cs, Inc. (OTC Bulletin Board: ARNI), a clinical-st...therapeutics, today announced its financial result... the year ended December 31, 2008, Arno reported a...mpared to a net loss of $3.4 million, or $0.34 per...expenses for the year ended December 31, 2008 were...
... panels for Operating & Exam Rooms, Patient Ed...CA (PRWEB) March 31, 2009 -- TrueVision® Syste...rosurgery, announced its new 3D 1080p flat panel p...y of Cataract and Refractive Surgery. For the fir...3D 1080p flat panel LCDs to display live and recor...
...c., a leader in human embryonic stem cell derived ... a validated kit to produce induced pluripotent st...isher. , , (Logo: http://www.newscom.com/c...pirit of collaboration ArunA Biomedical and Open B...ated induced pluripotent stem cell (iPS) kits cont...
Other Biology Technology:Arno Therapeutics Reports 2008 Year-End Financial Results 2Arno Therapeutics Reports 2008 Year-End Financial Results 3Arno Therapeutics Reports 2008 Year-End Financial Results 4Arno Therapeutics Reports 2008 Year-End Financial Results 5Arno Therapeutics Reports 2008 Year-End Financial Results 6TrueVision Adds 3D Flat Panel Displays to its Visualization Platform for Refractive-Cataract Surgery 2ArunA Biomedical Announces Co-development of Fully Validated Induced Pluripotent Stem Cell Kit 2
(Date:11/20/2009)...ss an ingenious mechanism for preventing oxygen fr...s the new finding of a team of biologists that inc...ch institute in Flanders, Belgium, connected to th...this discovery by modifying the DNA of the intesti... model organism, they have uncovered the existence...
(Date:11/20/2009)..., a respiratory disease commonly known as chronic ...se of death worldwide. 600 million people live wi... real treatment or cure, Grace Parraga of Robarts ...tario in London, Canada, is using various imaging ... , Parraga is a scientist in the Imaging Resea...
(Date:11/19/2009)...th an unwieldy name: 4-hydroxybutyrate (4-HB). Tak...pe drug. , Now, a team of Ohio and Michigan sci...s metabolized by the body. "This is new and import...r and chair of biological sciences at Michigan Tec... team. "It may provide new clues on how to counte...
Breaking Biology News(10 mins):Biologists discover bacterial defense mechanism against aggressive oxygen 2Gaining a better picture of lung disease 2Researchers begin to decipher metabolism of sexual assault drug 2Harvard scientists solve mystery about why HIV patients are more susceptible to TB infection 9069 1Harvard scientists solve mystery about why HIV patients are more susceptible to TB infection 9069 2Pennsylvania Patient Safety Authority Releases June Advisory 50410 1Pennsylvania Patient Safety Authority Releases June Advisory 50410 2Pennsylvania Patient Safety Authority Releases June Advisory 50410 3Pennsylvania Patient Safety Authority Releases June Advisory 50410 4Pennsylvania Patient Safety Authority Releases June Advisory 50410 5JAG Media Holdings Inc Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc 50405 1JAG Media Holdings Inc Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc 50405 2JAG Media Holdings Inc Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc 50405 3
...UNTAIN VIEW, Calif., Sept. 30 Audience today,anno...,s Wall Street,Journal Technology Innovation Award... By understanding the auditory pathway -- from the...ex -- Audience is the first company to,deliver a c... Scene,Analysis (ASA), or the grouping and process...
... WASHINGTON DC The Federation of American Scienti... TM the first biologically accurate immunology vi...SA Foundation (ESAF). This bold and fun game is av...ck . , "We expect to release the next version of ...man, project manager for the FAS Learning Technolo...
... NEW YORK (SEPTEMBER 30, 2008) Black ... pregnant at a younger age, and are more likely to...ildlife Conservation Society (WCS)., , The study,...Human-Wildlife Conflicts, tracked 12 bears over a...Tahoe, Nevada and compared them to 10 "wildland" b...
Other Biology News:Audience Selected as Silver Winner in This Year's Wall Street Journal Technology Innovation Awards and Winner of the Semiconductors Category 2Entertainment Software Association Foundation awards grant to FAS for immune attack 2Study: urban black bears 'live fast, die young' 2
TE Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade from Research Organics, Inc.
Xylene Resistant (X/R) Red System, 1000 Tests (SIGNET) from Covance Research Products, Inc
TE Buffer Solution, 1X, pH 8.0, sterile from Research Organics, Inc.
IHC Select TE Buffer pH 9.0 [Antigen/ Epitope Retrieval Reagent], 10x from CHEMICON
Biology Products: